Medroxyprogesterone Other names: Medroxyprogesterone acetate

Chemical formula: C₂₂H₃₂O₃  Molecular mass: 386.524 g/mol  PubChem compound: 6279

Therapeutic indications

Medroxyprogesterone is indicated for:

Dysfunctional (anovulatory) uterine bleeding

Population group: only adults (18 - 65 years old)

Anovular menstruation

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Secondary amenorrhoea

Population group: women, only adults (18 - 65 years old)

Secondary amenorrhea

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Mild to moderate endometriosis

Population group: women, only adults (18 - 65 years old)

Endometriosis (clinical)

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Contraception

Population group: women, only adults (18 - 65 years old)

Medroxyprogesterone is indicated for long-term female contraception. Each injection prevents ovulation and provides contraception for at least 12 weeks (+/- 5 days). However, it should be taken into consideration that the return to fertility (ovulation) may be delayed for up to one year.

Medroxyprogesterone is suitable for use in women who have been appropriately counselled concerning the likelihood of menstrual disturbance and the potential for a delay in return to full fertility.

Medroxyprogesterone may also be used for short-term contraception in the following circumstances:

  1. For partners of men undergoing vasectomy, for protection until the vasectomy becomes effective.
  2. In women who are being immunised against rubella, to prevent pregnancy during the period of activity of the virus.
  3. In women awaiting sterilisation.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Contraindications

Medroxyprogesterone is contraindicated in the following cases:

Hypersensitivity to medroxyprogesterone

Medroxyprogesterone allergy

Porphyria

Porphyria

Liver disease

Hepatopathy

Arterial thromboembolic disease

at least one of
Arterial embolic and thrombotic occlusion
Arterial thrombosis

Venous thromboembolism

Thromboembolism of vein

Breast cancer

Malignant tumor of breast

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

Summary of Product Characteristics (SPC) 2019: DEPO-PROVERA Suspension for injection
Summary of Product Characteristics (SPC) 2016: PROVERA Tablet
< Previous: Overview
Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈